BDBM298446 (4-((4-((4-(3-(5-(tert-Butyl)-2-methoxy-3-(methylsulfonamido)phenyl)ureido)naphthalen-1-yl)oxy)pyridin-2-yl)amino)-2-methoxyphenyl)(methyl)phosphinic acid::US10125100, Example 44::US10392346, Example 44::US10941115, Example 44::US9751837, Example 44

SMILES COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)ccc1P(C)(O)=O

InChI Key InChIKey=SUXULCDTOIYHQM-UHFFFAOYSA-N

Data  4 IC50  3 Kd

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 298446   

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298446(US10125100, Example 44 | (4-((4-((4-(3-(5-(tert-Bu...)
Affinity DataIC50: 1.10E+4nMAssay Description:ompounds of the invention were tested for inhibition of the human ether a go-go (hERG) channel using IonWorks patch clamp electrophysiology at Essen ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298446(US10125100, Example 44 | (4-((4-((4-(3-(5-(tert-Bu...)
Affinity DataIC50: 11nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298446(US10125100, Example 44 | (4-((4-((4-(3-(5-(tert-Bu...)
Affinity DataIC50: 20nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298446(US10125100, Example 44 | (4-((4-((4-(3-(5-(tert-Bu...)
Affinity DataIC50: 17nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lck(Human)
Oxular Acquisitions

US Patent
LigandPNGBDBM298446(US10125100, Example 44 | (4-((4-((4-(3-(5-(tert-Bu...)
Affinity DataKd:  5.30nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2021
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Oxular Acquisitions

US Patent
LigandPNGBDBM298446(US10125100, Example 44 | (4-((4-((4-(3-(5-(tert-Bu...)
Affinity DataKd:  1.90nMAssay Description:p38 MAPKα Method 1: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298446(US10125100, Example 44 | (4-((4-((4-(3-(5-(tert-Bu...)
Affinity DataKd:  6.60nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2021
Entry Details
Go to US Patent